Roche announces start of second part of Phase 2 clinical trials for SUNFISH
Sunfish examines RG7916 in people aged 2 – 25 years with Type 2/3 SMA.
Resources
Community Update by Roche – September 2017
The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.
Sunfish examines RG7916 in people aged 2 – 25 years with Type 2/3 SMA.
Resources
Community Update by Roche – September 2017